The post FDA Approves First Cell-Based Gene Therapy for Rare Skin Disorder appeared first on Novacore.

The post Growth of Value-Based Purchasing For Cell & Gene Therapies appeared first on Novacore.

The post FDA Approves Mesoblast’s First-Of-Its-Kind Cell Therapy appeared first on Novacore.

The post PTC Wins FDA Approval For First Brain-Delivered Gene Therapy Kebilidi appeared first on Novacore.

The post FDA Approves Aucatzyl for Adults with Aggressive Leukemia appeared first on Novacore.

The post Sequoia, IOA Re and Rockport Benefits Form Carbon Stop Loss Solutions appeared first on Novacore.

The post FDA Signs Off on Adaptimmune’s Tecelra appeared first on Novacore.

As cybercriminals target valuable health and personal data, cyberattacks are a growing threat for healthcare organizations and self-insured companies. In a feature article for The Self-Insurer, Carbon Stop Loss Solutions’ Director of Cost Containment Jakki Lynch explains that “beyond firewalls and multi-factor authentication, organizations should have a strategic preventative risk management and recovery plan for business continuity that includes alternative means of performing the operational services required for patient care delivery, revenue cycle management and claims adjudication.”

Read the full article, including Lynch’s considerations for mitigating risk exposure, here.

The post Overcoming Vulnerabilities For Stewards of Member Health Data appeared first on Novacore.

The post Sarepta Duchenne Gene Therapy Wins Broader Use From FDA appeared first on Novacore.

Beyond being a major public health challenge, obesity carries extreme implications for employers and their teams. In fact, a recent report estimates obesity cost U.S. employers and employees $425.5B in 2023. The study found that of the 158 million employees working in the private and government sectors, 30% were classified as obese, and 34% were overweight.

In this article for The Self-Insurer, Jakki Lynch, Carbon Stop Loss Solutions’ Director of Cost Containment, explains, “The direct costs of obesity are healthcare expenditures for medical treatment, preventative services, diagnostic testing, bariatric surgeries, and medications. While the newly approved drugs for weight management have recently gained considerable attention, they do not come without considerations for cost and health complications.”

Read the full article here.

The post The Dangers, Cost of Weight Loss Drugs — How to Avoid a Life Sentence appeared first on Novacore.